GWS
ALXN

Glassman Wealth Services’s Alexion Pharmaceuticals ALXN Stock Holding History

Glassman Wealth Services’s Portfolio ALXN Stock Details ALXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-289
Closed -$53K – 1916
2021
Q2 		$53K Buy
289
+22
+8% +$3.78K 0.01% 340
2021
Q1 		$41K Buy
267
+11
+4% +$1.7K 0.01% 365
2020
Q4 		$40K Buy
256
+29
+13% +$3.73K 0.01% 374
2020
Q3 		$26K Buy
227
+98
+76% +$10.6K 0.01% 401
2020
Q2 		$14K Buy
129
+85
+193% +$9.02K ﹤0.01% 442
2020
Q1 		$4K Buy
44
+31
+238% +$3.04K ﹤0.01% 579
2019
Q4 		$1K Buy
13
+9
+225% +$963 ﹤0.01% 1117
2019
Q3 		$0 Sell
4
-5
-56% -$564 ﹤0.01% 1504
2019
Q2 		$1K Hold
9
– – ﹤0.01% 999
2019
Q1 		$1K Sell
9
-3
-25% -$373 ﹤0.01% 966
2018
Q4 		$1K Hold
12
– – ﹤0.01% 726
2018
Q3 		$2K Hold
12
– – ﹤0.01% 630
2018
Q2 		$1K Buy
12
+8
+200% +$935 ﹤0.01% 761
2018
Q1 		$0 Sell
4
-3
-43% -$359 ﹤0.01% 981
2017
Q4 		$1K Sell
7
-13
-65% -$1.58K ﹤0.01% 636
2017
Q3 		$3K Hold
20
– – ﹤0.01% 405
2017
Q2 		$2K Sell
20
-21
-51% -$2.44K ﹤0.01% 435
2017
Q1 		$5K Buy
41
+29
+242% +$3.74K ﹤0.01% 406
2016
Q4 		$1K Buy
12
+9
+300% +$1.1K ﹤0.01% 592
2016
Q3 		$0 Buy
+3
New +$386 ﹤0.01% 615

Other funds holding ALXN

BCI
Brinker Capital Investments Berwyn, Pennsylvania $13.1B AUM 28.37% 1-Year Est. Return
NICM
Neo Ivy Capital Management New York $434M AUM 44.19% 1-Year Est. Return
TAIM
TD Ameritrade Investment Management Omaha, Nebraska $9.4B AUM 7.2% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $521B AUM 51.41% 1-Year Est. Return
RG
Retirement Group San Diego, California $279M AUM 22.21% 1-Year Est. Return
CFO
CVA Family Office Denver, Colorado $1.1B AUM 26.6% 1-Year Est. Return
MAM
Meeder Asset Management Dublin, Ohio $1.96B AUM 48.96% 1-Year Est. Return

Glassman Wealth Services's ALXN Position: Q3 2021 in Review

Glassman Wealth Services sold out of Alexion Pharmaceuticals (ALXN) in Q3 2021, closing a stake of 289 shares — an estimated $53K sold.

Glassman Wealth Services first reported a position in ALXN in Q3 2016 and held it in 20 quarters. The position peaked at $53K in Q2 2021. 7 funds tracked by Wall St. Rank hold ALXN as of Q3 2021.

  • Glassman Wealth Services reported no remaining Alexion Pharmaceuticals position as of Q3 2021 after selling out during the quarter.
  • Glassman Wealth Services sold 289 Alexion Pharmaceuticals shares in Q3 2021, an estimated $53K.
  • Glassman Wealth Services first reported a position in Alexion Pharmaceuticals in Q3 2016 and held it in 20 quarters.
  • Glassman Wealth Services's Alexion Pharmaceuticals position peaked at $53K in Q2 2021.
  • 7 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q3 2021.

Based on Glassman Wealth Services's 13F filing for Q3 2021, filed 10 Nov 2021.